The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: Single institution experience.
Samuray Tuncer
No relevant relationships to disclose
Mert Basaran
No relevant relationships to disclose
Burak Tanyildiz
No relevant relationships to disclose
Nesimi Buyukbabani
No relevant relationships to disclose
Gul Basaran
No relevant relationships to disclose
Oner Dogan
No relevant relationships to disclose